{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:44:05Z","timestamp":1789713845638,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008653","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":38,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008653.pub2","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T00:36:32Z","timestamp":1352421392000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Febuxostat for treating chronic gout"],"prefix":"10.1002","volume":"2012","author":[{"given":"Jean H","family":"Tayar","sequence":"first","affiliation":[{"name":"The University of Texas, M.D. Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"The University of Texas, M.D. Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"The University of Texas, M.D. Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd Unit 1465 Houston Texas USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"issue":"23","key":"10.1002\/14651858.CD008653.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008653.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"916\u201323","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a Novel Nonpurine Selective Inhibitor ofXanthine Oxidase:a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Goldfarb D. S.MacDonald P.Hunt B.Gunawardhana L American Journal of Kidney Diseases 2010 B59","DOI":"10.1053\/j.ajkd.2010.02.116"},{"issue":"6","key":"10.1002\/14651858.CD008653.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008653.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"R63 Apr 6","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0006|cit6","unstructured":"Whelton A Becker MA MacDonald P Hunt B Jackson RL International Journal of Rheumatic Diseases 2010 172 7"},{"issue":"11","key":"10.1002\/14651858.CD008653.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008653.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"issue":"8-9","key":"10.1002\/14651858.CD008653.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1081\/NCN-200027381","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase\/xanthine dehydrogenase (NPSIXO) in patients with gout and\/or hyperuricemia","volume":"23","author":"Komoriya","year":"2004","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0011|cit11","unstructured":"A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout Ongoing study March 2010"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0012|cit12","unstructured":"A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment Ongoing study April 2010"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0013|cit13","unstructured":"A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular harms of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities Ongoing study May 2010"},{"issue":"Art. No.:CD0083","key":"10.1002\/14651858.CD008653.pub2-BIB0014|cit14","first-page":"DOI: 10.1002\/14","article-title":"Pegloticase for chronic gout","volume":"Issue 3","author":"Anderson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008653.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Annals of Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD008653.pub2-BIB0016|cit16","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"12","key":"10.1002\/14651858.CD008653.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1345\/aph.1H121","article-title":"Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout","volume":"40","author":"Bruce","year":"2006","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0018|cit18","unstructured":"Cates C Visual Rx 2.0 NNT Calculator [Computer program] Dr Chris Cates EBM Website www.nntonline.net 2004"},{"issue":"2","key":"10.1002\/14651858.CD008653.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/BOR.0b013e328325bd94","article-title":"Update on emerging urate-lowering therapies","volume":"21","author":"Chohan","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008653.pub2-BIB0020|cit20","first-page":"391\u20135","article-title":"Allopurinol dosing in renal impairment: Walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"September\u2013October 2007","journal-title":"Seminars in Dialysis"},{"issue":"5","key":"10.1002\/14651858.CD008653.pub2-BIB0021|cit21","first-page":"673","article-title":"Enhanced purine salvage during allopurinol therapy: an important pharmacologic property in humans","volume":"98","author":"Edwards","year":"1981","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0022|cit22","first-page":"ii15","article-title":"Febuxostat: a new treatment for hyperuricaemia in gout","volume":"48 Suppl 2","author":"Edwards","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0023|cit23","unstructured":"European Medicines Agency European Public Assessment Report http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000777\/WC500021813.pdf"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0024|cit24","unstructured":"US Food Drug Administration Summary Review for Regulatory Action http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021856s000_SumR.pdf"},{"issue":"7414","key":"10.1002\/14651858.CD008653.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0026|cit26","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","article-title":"International position paper on febuxostat","volume":"29","author":"Jansen","year":"2010","journal-title":"Clinical Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD008653.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1002\/14651858.CD008653.pub2-BIB0029|cit29","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008653.pub2-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007277.pub2","article-title":"Abatacept for rheumatoid arthritis","author":"Maxwell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008653.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"October 2008","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD008653.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"21","key":"10.1002\/14651858.CD008653.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD008653.pub2-BIB0034|cit34","first-page":"2452\u20135","article-title":"Outcome measures for acute and chronic gout","volume":"32","author":"Schumacher","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008653.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/ar3110","article-title":"Advances in gout: some answers, more questions","volume":"12","author":"Singh","year":"2010","journal-title":"Arthritis Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD008653.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11535770-000000000-00000","article-title":"Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal","volume":"29","author":"Stevenson","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1002\/14651858.CD008653.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008653.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Annals of the Rheumatic Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008653.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:05:51Z","timestamp":1730678751000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008653.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008653.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}